Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Fake blood market gets hemoglobin transfusion from reticulocytes

Article Abstract:

Hemosol has demonstrated that it may no longer need to use donated blood as a hemoglobin source for its blood substitute product, Hemolink. Hemsol's laboratory cultures showed in vitro growth of human hemoglobin cells. This cell growth, which reached a one million-fold expansion in red blood cell precursors, was achieved by culturing CD34+ hematopoietic progentior cells derived from umbilical cord blood, and by adding selected cytokins for the formation of red blood cells, or reticulocyte blood cells. After thirty days, the reticulocyte cells produce hemoglobin, which can be purified. Hemosol believes this method will affect both the quality and availability of Hemolink.

Comment:

Hemolink demostrates that hemoglobin-producing cells can be produced in vitro

Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1998
Canada, Hemosol Inc., Article

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants?

Article Abstract:

Hemoglobin-based blood substitutes are being developed to carry oxygen to prevent ischemic tissue damage and hypovolemic (low blood volume) shock. Their usefulness for maintaining blood pressure has been analyzed because of the ability of cell-free hemoglobin blood substitutes to affect vascular tone through the removal of nitric oxide. Concerns remain about the clinical toxicity of the hemoglobin molecule.

Author: Alayash, Abdu I.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1999
United States

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Antisense and siRNA as agonists of Toll-like receptors

Article Abstract:

The ability of antisense and short-interfering ribonucleic acid (siRNA) agents to bind and activate Toll-like receptors (TLRs) is studied. The results indicate that the hybridization-based antisense and siRNA techniques could be considered as important tools for genomic studies, and could also play an important role in the development of therapeutics.

Author: Agarwal, Sudhir, Kandimalla, Ekambar R.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
Nucleic Acid Derivatives, Research, Gene expression, Nucleotides, Hybridization

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Blood substitutes
Similar abstracts:
  • Abstracts: Information quality and market share in electronic commerce. The applicability of SERVQUAL in cross-national measurements of health-care quality
  • Abstracts: Farm business marketing behavior and strategic groups in agriculture. Cotton producers' choice of marketing techniques
  • Abstracts: Setting the standards for the supply chain. A refined operator. A building of distinction
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.